Blood tests for protein biomarkers show promise

Non-invasive Blood Tests Hold Promise for Transplant Outcomes

transplant recipients in the fi rst year post-transplant are infection and rejection. Over time, transplant coronary artery disease (a form of chronic rejection) and malignancy (resulting from inadequate immune surveillance of cancer cells) emerge as threats. Balancing immune response is one of the most serious challenges for the transplant cardiologist: over-immunosuppression results in an inc...

Variable Ordering Heuristics Show Promise

ADCs Show Promise in Leukemias.

According to a phase III study, the antibody-drug conjugate inotuzumab ozogamicin is more likely to induce complete remissions, with full or incomplete hematologic recovery, in patients with relapsed or refractory acute lymphocytic leukemia. Data from a phase I study of another antibody-drug conjugate, vadastuximab talirine, demonstrates that it is safe and effective against acute myeloid leuke...

Circulating miRNAs in Pediatric Pulmonary Hypertension Show Promise as Biomarkers of Vascular Function

BACKGROUND/OBJECTIVES The objective of this study was to evaluate the utility of circulating miRNAs as biomarkers of vascular function in pediatric pulmonary hypertension. METHOD Fourteen pediatric pulmonary arterial hypertension patients underwent simultaneous right heart catheterization (RHC) and blood biochemical analysis. Univariate and stepwise multivariate linear regression was used to ...

Agents to control bleeding show promise.

Every year, thousands of patients develop deep vein thrombosis (DVT) and are at risk of pulmonary embolism after undergoing surgeries, particularly orthopedic procedures in the hips and legs. Although low-molecular-weight heparin is considered the standard therapy for DVT and other forms of venous thromboembolism, it is far from an ideal anticoagulant. Its drawbacks include the need for daily i...